BioPhorum appoints Uwe Buecheler as non-executive director
Ella Day | May 21, 2025 | Appointment | Medical Communications, Research and Development | BioPhorum, Corporate, appointment, biopharma, medical communication
BioPhorum has announced the appointment of Uwe Buecheler as a non-executive director to its board. The company brings together leaders from across the biopharma and medical device industries to address common challenges and promote cross-sector collaboration.
Buecheler brings more than three decades of experience in the biopharma industry, including leadership roles spanning development operations, strategic planning and regulatory affairs. He has been directly involved in over 30 biologics launches and has led programmes in CMC development, biosafety, quality and contract manufacturing.
During his role at Boehringer Ingelheim, Buecheler oversaw the expansion of the company’s global operations network, including projects in the US and China. He also supported the first Biologics Marketing Authorisation Holder (MAH) approval in Shanghai and contributed to major facility expansions in aseptic processing and large-scale mammalian cell culture manufacturing.
Deborah Kobewka, CEO of BioPhorum, said: “We are delighted to welcome Buecheler to our board of directors. His impressive track record and deep understanding of the biopharmaceutical sector make him an excellent addition to our team. His insights and leadership will be instrumental as BioPhorum continues to support collaboration and innovation across the industry.”
Buecheler commented: “I am thrilled to join BioPhorum’s board and contribute to its mission of driving progress through shared best practice. I look forward to working with the team to support meaningful advancements in the sector.”
Ella Day
21/5/25
Related Content
BioPhorum announces acquisition of Inspired Pharma
BioPhorum, a global pharmaceutical collaboration group, has announced the acquisition of Inspired Pharma, a provider …
Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …
University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase …
